Pfizer recalls Levoxyl 175 mcg levothyroxine sodium tablets over weaker-than-labeled strength
The tablets are subpotent, meaning they are weaker than labeled, after a stability test confirmed an out-of-specification assay result.
What to do
The notice does not give instructions. Read the official notice for details.
Note from Recalled Today: Don't stop taking a prescribed medicine before you talk to your pharmacist or doctor.
Recall details
- Product
- Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.; Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10
- Company
- Pfizer
- Hazard
- Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
- Units
- 15,815 100-count bottles; 134 1000-count bottles
- Where sold
- US Nationwide and Puerto Rico
- FDA classification
- Class II · Ongoing
- Classified by FDA
- October 16, 2026
- Recall started
- September 29, 2026
- FDA enforcement report
- October 28, 2026
- Identifiers
- Codes: Lot # 24W06, Exp: 11/30/2026
- FDA recall number: D-0052-2027
- Codes: Lot # 24W07, Exp: 11/30/2026
- FDA recall number: D-0051-2027
The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.
Official notice
The notice's own wording from FDA.
- Product
- Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01. | Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10
- Reason for recall
- Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
- Classification
- Class II (Ongoing)
- Distribution
- US Nationwide and Puerto Rico
- Quantity
- 15,815 100-count bottles; 134 1000-count bottles
Related recalls
Pfizer recalls Dopamine HCl Inj., USP, 200 mg/5 mL vials over lack of assurance of sterility
The notice says there is a lack of assurance of sterility for these 5 mL single-dose vials of Dopamine HCl Inj., USP, which were distributed nationwide in the US by Hospira, Inc.
Greenwich Rx recalls Glutathione Injection 10 mL vials over microbial contamination
The notice says the sterile Glutathione Injection (200 mg/mL, 10 mL multi-dose vial, Subcutaneous Only) has microbial contamination, and 4,319 vials were sent across the US.
Greenwich Rx · 4,319 vials
Pritam International recalls Brush Buddies and evo toothpastes over manufacturing practice problems
The notice says these anticavity fluoride toothpastes were made with deviations from current good manufacturing practices and were distributed across the US.
Pritam International Private Limited · 3,309,696 units
Strides Pharma recalls Cinacalcet Tablets 30 mg because they failed dissolution specifications
The 30 mg Cinacalcet Tablets in 30-count bottles failed dissolution specifications, and 49,488 bottles were distributed across the US.
Strides Pharma INC · 49,488 30-count bottles
Viatris recalls telmisartan and amlodipine tablets because telmisartan content may be too high
The tablets may contain more telmisartan than they are supposed to, so the content in these lots could go over the limit set for the product.
Viatris, Inc. · 21,620 30-count bottles
Ascend Laboratories recalls amlodipine and olmesartan medoxomil tablets because they failed a dissolution test
The 10mg/40mg tablets, sold in 30-tablet bottles, were found to be out of specification due to dissolution, and 11,424 bottles were distributed nationwide within the United States.
Ascend Laboratories, LLC · 11,424 bottles.